^
    Back
    Association details:
    Biomarker:EGFR G719A
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    N Engl J Med
    Title:

    Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

    Excerpt:
    First-line gefitinib for patients with advanced non–small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    10.1056/NEJMoa0909530
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

    Excerpt:
    ...- Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q)...
    Trial ID:
    NCT02804100
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

    Excerpt:
    Clinical outcomes for rare mutations or rare combinations of mutations
    DOI:
    10.1158/1078-0432.CCR-09-0888